KCPG
PACB icon

Kavar Capital Partners Group’s Pacific Biosciences PACB Stock Holding History

Kavar Capital Partners Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Buy
103,319
+10,000
+11% +$14.5K 0.02% 202
2026
Q1 		$123K Buy
+93,319
New +$167K 0.02% 211

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Kavar Capital Partners Group's PACB Position: Q2 2026 in Review

Kavar Capital Partners Group increased its Pacific Biosciences (PACB) stake by 11% in Q2 2026, buying an estimated $14.5K and bringing the position to 103,319 shares worth $174K. The position accounts for 0.02% of the portfolio, ranked #202.

Kavar Capital Partners Group first reported a position in PACB in Q1 2026 and has held it in 2 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Kavar Capital Partners Group held 103,319 shares of Pacific Biosciences worth $174K as of Q2 2026.
  • Kavar Capital Partners Group bought 10,000 Pacific Biosciences shares in Q2 2026, an estimated $14.5K.
  • Pacific Biosciences made up 0.02% of Kavar Capital Partners Group's portfolio in Q2 2026, its #202 holding.
  • Kavar Capital Partners Group first reported a position in Pacific Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Kavar Capital Partners Group's 13F filing for Q2 2026, filed 20 Jul 2026.